DaVita Shares Rise After TD Cowen Upgrades Stock to Buy
DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.
How this was made
The 30-second read
Why it matters
TD Cowen’s upgrade to Buy and higher price target are presented as a response to the earnings beat and a more constructive view of long-term growth, including a potential MOTheR trial treatment approach.
Market read
This is a same-day catalyst for DVA tied to a rating change and PT increase, layered on top of a recent earnings beat followed by guidance-related disappointment.
What to watch
The article flags potential risks including ongoing legal proceedings and the possibility of Berkshire Hathaway reducing its stake, which could cap upside despite the PT increase.
Background
DaVita reported Q2 2026 adjusted EPS and revenue above consensus, but shares fell after management maintained full-year guidance and noted a slight decline in revenue per treatment.
Ticker impact
DaVita shares rose premarket after TD Cowen upgraded it to Buy and raised its price target to $220 from $201.
Likely supports continued relative strength versus peers in early sessions, with follow-through dependent on how investors digest the maintained full-year guidance.
The article cites a same-day analyst action (rating and PT change) and ties it to DaVita’s recent earnings beat and subsequent guidance-related disappointment, which can drive incremental demand from traders.
Market effects
Upward PT revisions and a clinical-trial read-across narrative can lift sentiment for kidney dialysis and adjacent healthcare services names.
Primarily US premarket sentiment; no specific regional catalyst beyond broad index strength.
Limited direct global linkage; dialysis demand and clinical pipeline are globally relevant but not addressed with new international facts.
Counterpoint
The upgrade may be offset by the market’s focus on maintained full-year guidance and the reported slight reduction in revenue per treatment.
Key entities
- companyDaVita HealthCare Partners Inc.
US-listed kidney dialysis provider whose premarket move is attributed to an analyst upgrade and recent earnings/guidance details.
- analyst_firmTD Cowen
Brokerage that upgraded DaVita from Hold to Buy and raised its price target to $220 from $201.
- clinical_trialMOTheR trial
Trial results referenced as potentially enabling a new treatment approach supporting patient growth without major additional equipment investment.
- shareholderBerkshire Hathaway
Mentioned as a potential source of risk if it reduces its stake.
